Antiphospholipid Syndrome Review

Clinics in Laboratory Medicine

Volumn 29, Issue 2, 2009, Pages 305-319

  Eby, Charles ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 glycoprotein I; Anticardiolipin; Anticoagulant; Antiphospholipid syndrome; Lupus

Indexed keywords

ACETYLSALICYLIC ACID; AUTOANTIBODY; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; THROMBIN INHIBITOR; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; HUMAN; INFLAMMATION; LABORATORY TEST; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOSIS; TISSUE INJURY;

ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; FEMALE; FETAL DEATH; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; LUPUS COAGULATION INHIBITOR; PREGNANCY; THROMBOPLASTIN;

EID: 68149169958     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2009.06.001     Document Type: Review

References (65)

1. Conley C., and Hartmann R. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 31 (1952) 621-622
2. Bowie E.J., Thompson Jr. J.H., Pascuzzi C.A., et al. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 62 (1963) 416-430
3. Soulier J., and Boffa M. Avortement a repetition, thromboses, et anticoagulant circulant anti-thromboplastine. Nouv Presse Med 9 (1980) 859-864
4. Harris E.N., Gharavi A.E., Boey M.L., et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2 8361 (1983) 1211-1214
5. Mackworth-Young C.G., Loizou S., and Walport M.J. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 48 5 (1989) 362-367
6. Hughes G.R. The anticardiolipin syndrome. Clin Exp Rheumatol 3 4 (1985) 285-286
7. Gharavi A.E., Harris E.N., Asherson R.A., et al. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 46 1 (1987) 1-6
8. Harris E.N. Syndrome of the black swan. Br J Rheumatol 26 5 (1987) 324-326
9. Brandt J.T., Triplett D.A., Alving B., et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardization committee of the ISTH. Thromb Haemost 74 4 (1995) 1185-1190
10. Wilson W.A., Gharavi A.E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42 7 (1999) 1309-1311
11. McNeil H.P., Simpson R.J., Chesterman C.N., et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 87 11 (1990) 4120-4124
12. Giannakopoulos B., Passam F., Ioannou Y., et al. How we diagnose the antiphospholipid syndrome. Blood 113 5 (2009) 985-994
13. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 2 (2006) 295-306
14. Galli M., Luciani D., Bertolini G., et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101 5 (2003) 1827-1832
15. Galli M., Luciani D., Bertolini G., et al. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102 8 (2003) 2717-2723
16. Levine J.S., Branch D.W., and Rauch J. The antiphospholipid syndrome. N Engl J Med 346 10 (2002) 752-763
17. Merrill J.T., and Asherson R.A. Catastrophic antiphospholipid syndrome. Nat Clin Pract Rheumatol 2 2 (2006) 81-89
18. Asherson R.A. The primary, secondary, catastrophic, and seronegative variants of the antiphospholipid syndrome: a personal history long in the making. Semin Thromb Hemost 34 3 (2008) 227-235
19. Wong R.C., and Favaloro E.J. Clinical features, diagnosis, and management of the antiphospholipid syndrome. Semin Thromb Hemost 34 3 (2008) 295-304
20. Jennings I., Kitchen S., Woods T.A., et al. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for blood coagulation. Thromb Haemost 77 5 (1997) 934-937
21. Arnout J., Meijer P., and Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb Haemost 81 6 (1999) 929-934
22. Favaloro E.J., and Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 118 4 (2002) 548-557
23. Favaloro E.J., Wong R.C., Jovanovich S., et al. A review of beta2 -glycoprotein-l antibody testing results from a peer-driven multilaboratory quality assurance program. Am J Clin Pathol 127 3 (2007) 441-448
24. Favaloro E.J., and Wong R.C. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. Semin Thromb Hemost 34 4 (2008) 389-410
25. Thiagarajan P., Pengo V., and Shapiro S.S. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 68 4 (1986) 869-874
26. Tripodi A. Laboratory testing for lupus anticoagulants: diagnostic criteria and use of screening, mixing, and confirmatory studies. Semin Thromb Hemost 34 4 (2008) 373-379
27. Le Querrec A., Arnout J., Arnoux D., et al. Quantification of lupus anticoagulants in clinical samples using anti-beta2GPI and anti-prothrombin monoclonal antibodies. Thromb Haemost 86 2 (2001) 584-589
28. Devreese K., and Hoylaerts M. Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome. Eur J Haematol 83 (2009) 1-16
29. Gardiner C., MacKie I.J., Malia R.G., et al. The importance of locally derived reference ranges and standardized calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant. Br J Haematol 111 4 (2000) 1230-1235
30. Rosner E., Pauzner R., Lusky A., et al. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost 57 2 (1987) 144-147
31. Jacobsen E.M., Barna-Cler L., Taylor J.M., et al. The lupus ratio test: an interlaboratory study on the detection of lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test. Fifth International Survey of Lupus Anticoagulants-ISLA 5. Thromb Haemost 83 5 (2000) 704-708
32. Tripodi A., Biasiolo A., Chantarangkul V., et al. Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem 49 10 (2003) 1608-1614
33. Favaloro E.J. Preanalytical variables in coagulation testing. Blood Coagul Fibrinolysis 18 1 (2007) 86-89
34. Greaves M., Cohen H., Machin S.J., et al. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 109 4 (2000) 704-715
35. Jacobsen EM, Trettenes E, Wisloff F, et al. Detection and quantification of lupus anticoagulants in plasma from heparin treated patients, using addition of polybrene. Thromb J. Available at: http://www.thrombosisjournal.com/content/pdf/1477-9560-4-3.pdf. Accessed May 26, 2009.
36. Aboud M.R., Roddie C., Ward C.M., et al. The laboratory diagnosis of lupus anticoagulant in patients on oral anticoagulation. Clin Lab Haematol 28 2 (2006) 105-110
37. Harris E.N., Gharavi A.E., Patel S.P., et al. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 68 1 (1987) 215-222
38. Passam F., and Krilis S. Laboratory tests for the antiphospholipid syndrome: current concepts. Pathology 36 2 (2004) 129-138
39. Pengo V., Biasiolo A., Bison E., et al. Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-glycoprotein I activity. Thromb Res 120 1 (2007) 127-133
40. Pengo V. A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome. J Thromb Haemost 6 6 (2008) 1048-1049
41. Galli M., Reber G., de Moerloose P., et al. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 6 2 (2008) 399-401
42. Vila P., Hernandez M.C., Lopez-Fernandez M.F., et al. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 72 2 (1994) 209-213
43. Alarcon-Segovia D., Boffa M.C., Branch W., et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 12 7 (2003) 499-503
44. Cervera R., Piette J.C., Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46 4 (2002) 1019-1027
45. Crowther M.A., Ginsberg J.S., Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349 12 (2003) 1133-1138
46. Finazzi G., Marchioli R., Brancaccio V., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3 5 (2005) 848-853
47. Schulman S., Svenungsson E., and Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 104 4 (1998) 332-338
48. Kearon C., Kahn S.R., Agnelli G., et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 6 Suppl (2008) 454S-545S
49. Mohr J.P., Thompson J.L., Lazar R.M., et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345 20 (2001) 1444-1451
50. Brey R.L., Chapman J., Levine S.R., et al. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 12 7 (2003) 508-513
51. Ruiz-Irastorza G., Hunt B.J., and Khamashta M.A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 57 8 (2007) 1487-1495
52. Erkan D., Merrill J.T., Yazici Y., et al. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 44 6 (2001) 1466-1467
53. Laskin C.A., Spitzer K.A., Clark C.A., et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 36 2 (2009) 279-287
54. Tincani A., Branch W., Levy R.A., et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 12 7 (2003) 524-529
55. Gates S, Brocklehurst P, Davis L. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev 2002(2):CD14001689.
56. Moll S., and Ortel T.L. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 127 3 (1997) 177-185
57. Tripodi A., Chantarangkul V., Clerici M., et al. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 115 3 (2001) 672-678
58. Rosborough T.K., and Shepherd M.F. Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant. Pharmacotherapy 24 7 (2004) 838-842
59. Fleck R.A., Rapaport S.I., and Rao L.V. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 72 2 (1988) 512-519
60. Baca V., Montiel G., Meillon L., et al. Diagnosis of lupus anticoagulant in the lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature. Am J Hematol 71 3 (2002) 200-207
61. Erkan D., Bateman H., and Lockshin M.D. Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature. Lupus 8 7 (1999) 560-564
62. Urbanus R.T., Derksen R.H., and de Groot P.G. Platelets and the antiphospholipid syndrome. Lupus 17 10 (2008) 888-894
63. de Groot P.G., and Derksen R.H. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 3 8 (2005) 1854-1860
64. Redecha P., Tilley R., Tencati M., et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 110 7 (2007) 2423-2431
65. Girardi G., Redecha P., and Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10 11 (2004) 1222-1226